Tislelizumab in Asian patients with previously treated locally advanced or metastatic urothelial carcinoma

Tislelizumab, an anti‐programmed death protein‐1 (PD‐1) monoclonal antibody, was engineered to minimize binding to the FcγR on macrophages to abrogate antibody‐dependent phagocytosis, a mechanism of T‐cell clearance and potential resistance to anti‐PD‐1 therapy. This single‐arm phase 2 trial (NCT040...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Cancer Sci
Prif Awduron: Ye, Dingwei, Liu, Jiyan, Zhou, Aiping, Zou, Qing, Li, Hanzhong, Fu, Cheng, Hu, Hailong, Huang, Jian, Zhu, Shaoxing, Jin, Jie, Ma, Lulin, Guo, Jianming, Xiao, Jun, Park, Se Hoon, Zhang, Dahong, Qiu, Xiusong, Bao, Yuanyuan, Zhang, Lilin, Shen, Wei, Bi, Feng
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: John Wiley and Sons Inc. 2020
Pynciau:
Clinical Research
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC7780053/
https://ncbi.nlm.nih.gov/pubmed/33047430
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/cas.14681
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg